Consensus on Treatment for Mucopolysaccharidosis Type I
Author Information
Author(s): de Ru Minke H, Boelens Jaap J, Das Anibh M, Jones Simon A, van der Lee Johanna H, Mahlaoui Nizar, Mengel Eugen, Offringa Martin, O'Meara Anne, Parini Rossella, Rovelli Attilio, Sykora Karl-Walter, Valayannopoulos Vassili, Vellodi Ashok, Wynn Robert F, Wijburg Frits A
Primary Institution: Academic Medical Center, University of Amsterdam
Hypothesis
What are the optimal treatment strategies for patients with mucopolysaccharidosis type I?
Conclusion
The consensus procedure established key treatment guidelines for mucopolysaccharidosis type I, emphasizing the importance of early intervention and collaboration among specialists.
Supporting Evidence
- Early treatment with HSCT can preserve cognitive function in MPS I-H patients.
- All patients with MPS I may benefit from enzyme replacement therapy.
- Consensus was reached on the importance of a multidisciplinary approach to treatment.
Takeaway
Doctors agree that kids with a serious form of a disease called MPS I should get a specific treatment before they turn 2.5 years old to help them stay healthy.
Methodology
A modified Delphi process was used with a panel of specialists to develop consensus-based statements on treatment options for MPS I.
Potential Biases
Potential bias may arise from the varying opinions of specialists in metabolic disorders and bone marrow transplantation.
Limitations
The study is limited by the rarity of the disease, which restricts the amount of available empirical evidence.
Participant Demographics
The panel included 8 metabolic disorder specialists and 7 bone marrow transplant physicians.
Statistical Information
P-Value
p=0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website